Side population cells isolated from human osteosarcoma are enriched with tumor-initiating cells

Cancer Science

Volumn 102, Issue 10, 2011, Pages 1774-1781

  Yang, Min ^a   Yan, Ming ^a   Zhang, Rui ^b   Li, Jing ^a   Luo, Zhuojing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CD133 ANTIGEN; HERMES ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; RNA; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR NANOG;

ARTICLE; CARCINOGENICITY; CELL ISOLATION; CELL REGENERATION; CLINICAL ARTICLE; CLONOGENESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PRIORITY JOURNAL; SIDE POPULATION CELL; STEM CELL; UPREGULATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD44; ATP-BINDING CASSETTE TRANSPORTERS; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOPROTEINS; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PEPTIDES; PROTO-ONCOGENE PROTEINS C-KIT; SIDE-POPULATION CELLS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 80053384729     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02028.x     Document Type: Article

References (33)

1. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003; 3: 685-94.
2. Tang N, Song WX, Luo J et al. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008; 466: 2114-30.
3. Bielack SS, Carrle D, Hardes J et al. Bone tumors in adolescents and young adults. Curr Treat Options Oncol 2008; 9: 67-80.
4. Akiyama T, Dass CR, Choong PF. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 2008; 7: 3461-9.
5. Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials 2008; 3: 228-31.
6. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 2008; 10: 315-27.
7. Gibbs CP, Kukekov VG, Reith JD et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005; 7: 967-76.
8. Berman SD, Calo E, Landman AS et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA 2008; 105: 11851-6.
9. Tirino V, Desiderio V, d'Aquino R et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS ONE 2008; 3: e3469.
10. Wu C, Wei Q, Utomo V et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 2007; 67: 8216-22.
11. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-84.
12. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004; 23: 7274-82.
13. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006; 66: 4553-7.
14. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002; 99: 507-12.
15. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
16. Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506-11.
17. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-37.
18. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-15.
19. Patrawala L, Calhoun T, Schneider-Broussard R et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-708.
20. Patrawala L, Calhoun T, Schneider-Broussard R et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-19.
21. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-33.
22. Haraguchi N, Utsunomiya T, Inoue H et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24: 506-13.
23. Chiba T, Kita K, Zheng YW et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-51.
24. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-9.
25. Zhou S, Schuetz JD, Bunting KD et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-34.
26. Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-133.
27. Mitsutake N, Iwao A, Nagai K et al. Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 2007; 148: 1797-803.
28. Goodell MA, Rosenzweig M, Kim H et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3: 1337-45.
29. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340-58.
30. Szakács G, Paterson JK, Ludwig JA et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
31. Chambers I, Colby D, Robertson M et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003; 113: 643-55.
32. Mitsui K, Tokuzawa Y, Itoh H et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003; 113: 631-42.
33. Adhikari AS, Agarwal N, Wood BM et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010; 70: 4602-12.